CORDIS
EU research results

CORDIS

English EN
Female Reproductive toxicity of EDCs: a human evidence-based screening and Identification Approach

Female Reproductive toxicity of EDCs: a human evidence-based screening and Identification Approach

Objective

The FREIA consortium aims to close gaps in scientific knowledge on the mechanisms by which EDCs can affect female reproduction during specific life stages and will provide test methods to address this. The FREIA consortium has human tissue models that span the entire life cycle from fetal ovarian and adrenal tissues to child and mature ovarian follicles, that will be used identify human relevant biomarkers of EDC exposure. We will measure chemical exposures in follicular fluids and molecular profiles in granulosa cells from two IVF cohorts, and link these to fertility outcomes and patient journal information, including life-style factors and workplace. We will perform in vivo rodent studies to capture susceptible windows of exposure and identify novel endpoints for female reproductive toxicity that may be implemented in OECD test guidelines. We will provide in vitro test methods, according to OECD guidelines, for molecular and cellular events that have been implicated in female reproductive toxicity. These include ER-beta activity, GPER activity, ovarian-specific steroidogenesis, oocyte maturation and competency and hypothalamic pulsatile GnRH secretion. We will also develop QSAR models to predict interaction with aromatase and PPAR-gamma. By integrating our data from in vitro studies with primary human tissues, human exposure data from fetal and follicular fluid samples and our in vitro and in vivo research findings, the outcomes of FREIA are directly applicable to the human situation. AOPs will be developed that will form the basis for a test strategy to assess female reproductive toxicity upon exposure to EDCs, in a regulatory context. Furthermore, by expanding our scientific knowledge, the FREIA project will provide better information on EDC-related female reproductive health effects that will be used to improve reproductive health for women around the world.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

STICHTING VU

Address

De Boelelaan 1105
1081 Hv Amsterdam

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 529 108,75

Participants (10)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITEIT UTRECHT

Netherlands

EU Contribution

€ 239 481,25

THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN

United Kingdom

EU Contribution

€ 783 130

DANMARKS TEKNISKE UNIVERSITET

Denmark

EU Contribution

€ 1 025 796,25

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 456 387,50

UNIVERSITE DE LIEGE

Belgium

EU Contribution

€ 463 843,75

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 493 750

THE QUEEN'S UNIVERSITY OF BELFAST

United Kingdom

EU Contribution

€ 398 915

TERVISETEHNOLOOGIATE ARENDUSKESKUS AS

Estonia

EU Contribution

€ 311 375

UPPSALA UNIVERSITET

Sweden

EU Contribution

€ 200 948,75

TRUSTEES OF TUFTS COLLEGE CORPORATION

United States

EU Contribution

€ 201 740

Project information

Grant agreement ID: 825100

Status

Ongoing project

  • Start date

    1 January 2019

  • End date

    31 December 2023

Funded under:

H2020-EU.3.1.1.

  • Overall budget:

    € 6 104 476,25

  • EU contribution

    € 6 104 476,25

Coordinated by:

STICHTING VU

Netherlands